Spruce Biosciences FY2025 R&D expenses fell 57.97% to USD 19.5 million, net loss was USD 39 million

Reuters03-21
<a href="https://laohu8.com/S/SPRB">Spruce Biosciences</a> FY2025 R&D expenses fell 57.97% to USD 19.5 million, net loss was USD 39 million
  • Spruce published a Form 8-K reporting full-year 2025 results and corporate updates, including that a BLA submission for TA-ERT in MPS IIIB is expected in Q4 2026 after FDA Type B meetings.
  • Cash and cash equivalents were USD 48.9 million as of Dec. 31, 2025, excluding USD 15.0 million in gross proceeds from an Avenue Capital loan facility; the company said cash is expected to fund its operating plan into early 2027.
  • R&D expenses fell 58.02% to USD 19.5 million, primarily due to stopping tildacerfont development in CAH, partly offset by TA-ERT development and the acquisition of SPR202.
  • G&A expenses rose 16.44% to USD 17.0 million, driven mainly by higher professional service fees and partially offset by lower stock-based compensation.
  • Net loss narrowed 26.42% to USD 39.0 million, while total operating expenses decreased 40.26% to USD 36.5 million and included USD 2.6 million of non-cash stock-based compensation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-117888), on March 20, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment